Table 3.

Eosinophilia as a predictor of subsequent hypersensitivity reactions among patients undergoing outpatient parenteral antimicrobial therapy (OPAT).

	Eosinophilia† (N=210)	Never Eosinophilia (N=614)	Univariate Hazard Ratio‡ [95% CI]	Multivariate Hazard Ratio‡§ [95% CI]	Multivariate P-value‡§
Potential exposure time in person months (p-m)	203.8†	870.1
Rash, N	32	36	4.16 [2.54, 6.81]****	4.16 [2.54, 6.83]	<0.0001
Proportion	15%	6%
Rate per p-m	0.157	0.041
Renal injury, N	31	62	2.38 [1.52, 3.70]***	2.13 [1.36, 3.33]	0.0009
Proportion	15%	10%
Rate per p-m	0.152	0.071
Liver injury, N	13	41	1.57 [0.82, 2.96]	1.75 [0.92, 3.33]	0.09
Proportion	6%	7%
Rate per p-m	0.064	0.047
Any Injury‖, N	64	127	2.68 [1.97, 3.65]****	2.65 [1.94, 3.62]	<0.0001
Proportion	30%	21%
Rate per p-m	0.314	0.146

Abbreviations: p-m: person-months

^†Period after onset of eosinophilia.

^‡Cox model also incorporates the time and events in the eosinophilia group prior to onset of eosinophilia (109.0 person-months, 14 injuries, 2 rashes, 5 renal injuries, 7 liver injuries) with the never eosinophilia data.

^§Based on Cox proportional hazards model adjusted for age, gender, and antibiotics. Antibiotics were considered for multivariate model if univariate p-value < 0.50 and greater than 1% any-use during OPAT follow-up. Antibiotic inclusion in final multivariate model was based on backwards elimination. Vancomycin was included in multivariate model for renal injury (HR=2.53 [1.69, 3.80], p<0.0001) and for any HSR (HR=1.70 [1.29, 2.25], p=0.0002). No other antibiotics were included in multivariate models for HSR.

^‖Rash,, renal injury or liver injury.

^*<0.05,

^**<0.01,

^***<0.001,

^****<0.0001